Demand for weight-loss drugs surged throughout 2024, outpacing supply for most of the year. In December, Novo Holdings, an investment foundation of Novo Nordisk, acquired three manufacturing sites ...

Novo Nordisk, the maker of injectible weight loss drugs Ozempic and Wegovy, says a late-stage trial found that a high-dose oral version of the drug helped overweight adults lose 15 per cent of ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Shares in Denmark's Novo Nordisk soared more than 8% after early trial data for its experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment ...

Novo Nordisk has today launched its weight-loss injection Wegovy in Britain, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk said patients taking its one-a-day experimental drug, amycretin, lost 13 per cent of their body weight in 12 weeks. This compared to six per cent after the same time injecting Wegovy.

Little more than a month since becoming Europe’s most valuable listed company, Novo Nordisk has stretched its lead to over $100bn (€95bn) as the buzz around weight-loss drugs gets ever louder.

Novo Nordisk A/S has a successor waiting in the wings for the generation of weight-loss shots it pioneered: a pill that helps people shed pounds without the drawbacks of an injection.

Novo Nordisk: How weight loss jab bet paid off for Denmark's biggest firm as it plans to take on more diseases. The giant Danish enterprise is backed staunchly by a foundation with very clear ...